Lilly, Novo Sink on FDA List of Foreign GLP-1 Manufacturers

Shares of Eli Lilly & Co. and Novo Nordisk A/S fell after US regulators established a “green list” of foreign manufacturers who produce raw materials that compounding pharmacies use to make copies of their blockbuster GLP-1 drugs.

The Food and Drug Administration said in a statement Friday that, in an effort to block the importation of potentially dangerous versions of the active ingredients used in drugs like Wegovy and Mounjaro, it would publish a list of overseas suppliers that appear to comply with the agency’s standards. Compounding pharmacies use these raw materials to make their own versions of the brand-name drugs.